|
CINV related health state probabilities
|
|
Complete response in acute phase in PALO regimen
|
0.918
|
95% CI
|
[7]
|
|
Complete response in delayed phase in PALO regimen
|
0.672
|
95% CI
|
[7]
|
|
Complete response in acute phase in GRA regimen
|
0.918
|
95% CI
|
[7]
|
|
Complete response in delayed phase in GRA regimen
|
0.591
|
95% CI
|
[7]
|
|
Costs
|
JPY (USD)
|
JPY (USD)
| |
|
Palonosetron 0.75 mg (IV)
|
14,972 (133.5)
|
7,486-14,972 (66.7-133.5)
|
[15]
|
|
Granisetoron 1 mg (IV)
|
1,273 (11.3)
|
590 -1,273 (5.26-11.3)
|
[15]
|
|
Aprepitantcapusule set (125 mg /80 mg /80 mg) (PO)
|
11,638.2 (103.8)
| |
[15]
|
|
Dexametazone 2 mg (IV)
|
99 (0.883)
| |
[15]
|
|
Dexametazone 4 mg (PO)
|
34 (0.303)
| |
[15]
|
|
Blood testb
|
1,580 (14.1)
| |
[16]
|
|
Internal medicine for rescue medication for PALO regimen
|
432 (3.85)
|
± 30%
|
[15, 18, 19]
|
|
Internal medicine for rescue medication for GRA regimen
|
5,956.5 (53.1)
|
± 30%
|
[15, 18, 19]
|
|
Infusion therapy for rescue medication
|
1,374 (12.3)
|
± 30%
|
[15, 16, 18, 19]
|
|
Total cost per acute CINV in PALO regimen
|
432 (3.85)
| | |
|
Total cost per delayed CINV in PALO regimen
|
2,396 (21.36)
| | |
|
Total cost per acute CINV in GRA regimen
|
5,956.5 (53.10)
| | |
|
Total cost per delayed CINV in GRA regimen
|
10,221 (91.12)
| | |
|
Utility values
|
|
Complete protection
|
0.9
|
± 30%
|
[13, 14, 20,21,22]
|
|
Complete response at best
|
0.7
|
± 30%
|
[13, 14, 20,21,22]
|
|
Incomplete response
|
0.2
|
± 30%
|
[13, 14, 20,21,22]
|
